目的研究肝硬变患者前列腺素Ｅ１治疗后血清ＨＡ，ＰⅢＰ，ＣⅣ变化的临床意义．方法采用特异ＲＩＡ测定７０例肝硬变患者和３０例正常人血清透明质酸（ＨＡ）、Ⅲ型前胶原肽（ＰⅢＰ）、血清Ⅳ型胶原（ＣⅣ）的含量．肝硬变患者随机分成两组，对照组３０例为综合治疗组，实验组为综合治疗加前列腺素Ｅ１（ＰＧＥ１）．两组治疗前以上观察指标无显著差异（Ｐ＞００５）．按Ｃｈｉｌｄ分级，治疗前患者血清ＨＡ，ＰⅢＰ，ＣⅣ水平两组均为Ａ级＜Ｂ级＜Ｃ级．两组治疗４ｗｋ后再测定血清ＨＡ，ＰⅢＰ，ＣⅣ含量．结果肝硬变患者血清ＨＡ，ＰⅢＰ，ＣⅣ明显高于正常组（μｇ／Ｌ；９８２±６５８，２４８±４６，１６８±４１，ｖｓ２５３±１０，９３±１８，８１±３１；Ｐ＜００１）．实验组Ａ，Ｂ两级患者治疗后血清ＨＡ，ＰⅢＰ，ＣⅣ显著下降，Ａ级：４２９±３２６，１６６±１２，１２６±２１；Ｂ级：６８６±４１９，２６７±２１，１６９±３０；ｖｓＡ级：２６９±１５１，９６±２０，８６±１０，Ｂ级：４１９±３２６，１５０±３６，１１１±３１；Ｐ＜００１）．对照组治疗后血清ＨＡ，ＰⅢＰ，ＣⅣ也下降，Ａ级：４３２±３２５，１６５±１２，１２８±２２，Ｂ级：６９０±４２? Objective To study the clinical significance of serum HA, PⅢP and CⅣ in patients with cirrhosis after prostaglandin E1 treatment. Methods The levels of serum hyaluronic acid (HA), type Ⅲ procollagen peptide (P Ⅲ P) and serum type Ⅳ collagen (C Ⅳ) in 70 patients with cirrhosis and 30 normal individuals were determined by specific RIA. Patients with cirrhosis were randomly divided into two groups, 30 cases in the control group as the comprehensive treatment group, the experimental group for the comprehensive treatment plus prostaglandin E1 (PGE1). There was no significant difference between the two groups before treatment (P> 005). According to Child’s classification, the levels of serum HA, PⅢP and CⅣ in patients before treatment were A level